Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers
This two-year study follows 60 people with Charcot-Marie-Tooth disease type 1A (CMT1A). The main goal is to understand why CMT1A affects people differently and to find ways to predict how the disease might progress. Researchers will collect information like physical assessments, nerve tests, and blood samples. They also want to identify valuable tools that can be used in future studies to test new treatments for CMT1A. By participating, you could help scientists gain a clearer picture of CMT1A, which may lead to better ways to manage and treat this condition in the future.
At a glance
What is this study about?
This research is looking at Charcot-Marie-Tooth disease type 1A (CMT1A), which is a condition that affects the nerves, mainly in your arms and legs. We know that CMT1A can affect people in different ways, even with the same diagnosis. This study aims to understand why this happens and to find ways to predict how the disease might change over time for each person.
To do this, researchers will follow 60 people with CMT1A for two years. They will collect information through physical check-ups, special tests that look at how your nerves are working (called electrophysiological records), scans of your muscles (Muscle MRI), and blood samples. By gathering all this information, they hope to discover important clues that explain the differences seen in people with CMT1A.
Ultimately, this study wants to find better ways to measure how CMT1A affects people. These new measurement tools could then be used in future research to test new medications or treatments. This means that if this study is successful, it could pave the way for more effective clinical trials and potentially better treatments for CMT1A down the line.
Key takeaways
- This study aims to better understand Charcot-Marie-Tooth disease type 1A (CMT1A).
- It will follow 60 people with CMT1A for two years.
- Researchers want to find ways to track disease changes and predict its progression.
- Data from physical exams, nerve tests, MRI scans, and blood samples will be collected.
- The goal is to develop better tools for testing new treatments in the future.
- You will not receive any new medicines as part of this study.
Who may be eligible?
To join this study, you must have Charcot-Marie-Tooth disease type 1A (CMT1A), and your diagnosis needs to be confirmed by a genetic test showing a specific change on chromosome 17.
There are certain reasons why you might not be able to participate. For example, if you have other health conditions that affect your nerves, like diabetes, or if you have diseases such as HIV or cancer. If you've had a significant health issue get worse in the last month, or if you've had certain injuries or surgery recently, you also wouldn't be able to join.
Additionally, you can't be pregnant or breastfeeding. If you're taking certain anti-inflammatory medications, have issues with alcohol or drug misuse, or if you have a medical reason that prevents you from having an MRI scan, you wouldn't be able to take part. The study is open to both men and women between 18 and 70 years old.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Do you have a confirmed diagnosis of Charcot-Marie-Tooth disease type 1A (CMT1A) by a genetic test?
- Are you between 18 and 70 years old?
- Do you have any other significant health conditions like diabetes, HIV, or cancer?
- Are you pregnant or breastfeeding?
- Are you able to have an MRI scan?
- Have you had any major health issues or recent surgery (in the last 6 months)?
What does participation involve?
If you decide to take part in this study, you will be followed by the research team for two years. During this time, you will have several appointments where doctors will perform physical examinations to check on your condition. You will also undergo special tests that measure how your nerves are working, known as electrophysiological recordings. Your muscles will be scanned using an MRI to get detailed pictures.
Blood samples will be taken at different points during the study. These samples will be analysed to look for specific markers related to your disease. The researchers will not be giving you any new medication as part of this study. You should expect to have regular visits spread out over the two-year period, but the exact number and timing of these visits will be explained in detail by the study team.
Potential risks and benefits
Locations (2)
- Assistance Publique Hôpitaux de MarseilleVerified postcodeMarseille, France
- CHU Gui de Chauliac, CHU MONTPELLIERVerified postcodeMontpellier, France
Common questions
What is Charcot-Marie-Tooth disease type 1A (CMT1A)?
CMT1A is a common inherited condition that affects the nerves, mainly in your arms and legs. It can cause muscle weakness and numbness, and people experience it differently.
Will I receive any new treatment in this study?
No, this study is observing how CMT1A progresses and is not testing a new medication or treatment. You will continue with your usual medical care.
How long will I be involved in the study?
If you join, you will be part of the study for two years. You will have several appointments during this time.
What kind of tests will I have?
You will have physical check-ups, nerve tests (electrophysiological records), muscle scans (MRI), and blood samples taken.
Can I leave the study if I change my mind?
Yes, you can leave the study at any time, for any reason, without telling anyone why. It will not affect your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.